Analysis of Meloxicam in Accordance with the United States Pharmacopoeia by Nexera XR

Význam tématu

Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) commonly prescribed for arthritis and musculoskeletal disorders. Reliable quantification of meloxicam and its related impurities is essential to guarantee drug safety, efficacy, and regulatory compliance according to pharmacopeial standards.

Cíle a přehled studie / článku

This work demonstrates the application of the United States Pharmacopeia (USP) HPLC method for meloxicam analysis using the Nexera XR system. Key objectives include verifying system suitability for both assay and impurity determinations, and evaluating the compatibility of methods transferred to Shimadzu’s Prominence series via the ACTO function.

Použitá instrumentace

• Nexera XR high‐performance liquid chromatography system with PDA detector.
• Shim-pack GIST C18 column (150 × 4.6 mm, 5 µm; USP L1).
• Prominence HPLC systems for method transfer comparison.
• LabSolutions software with ACTO (Analytical Condition Transfer and Optimization) module.

Metodika

• Assay (isocratic): mobile phase methanol/aqueous solution A (21/29), flow rate 1 mL/min, column temp. 45 °C, detection at 360 nm, injection 10 µL.
• Solution A for assay: 0.1% ammonium acetate adjusted to pH 9.1 with ammonia; diluent methanol/1 N NaOH (250:1).
• Impurity analysis (gradient): solution A monobasic potassium phosphate pH 6.0, B methanol; gradient 40–70% B over 15 min, flow 1 mL/min, column temp. 45 °C, detection 350 nm and 260 nm, injection 5 µL.
• Preparation of system suitability and standard solutions as per USP concentrations.

Hlavní výsledky a diskuse

• All system suitability tests met USP criteria: resolution > 3.0, tailing factor < 2.0, RSD for peak area < 2% (assay) and < 10% (impurity).
• Relative retention times for assay impurity A (0.6 vs. USP 0.7) and gradient impurities B and A (0.5 and 1.3 vs. USP 0.4 and 1.4) were within acceptable ranges.
• Chromatograms showed clear separation of meloxicam and related compounds with high peak symmetry.
• ACTO-based adjustment of gradient delay volumes enabled comparable chromatograms on Prominence systems (mixer volumes 0.5–2.7 mL) without hardware changes.

Přínosy a praktické využití metody

This optimized USP-compliant HPLC protocol provides a robust quality control tool for pharmaceutical manufacturers. The ACTO function facilitates seamless method transfer between different HPLC platforms, reducing downtime and validation burden.

Budoucí trendy a možnosti využití

• Integration of automated method transfer and optimization software to support multi-site laboratory harmonization.
• Expansion towards coupling with mass spectrometry detectors for enhanced impurity profiling.
• Development of greener mobile phases and accelerated run times to improve sustainable throughput.

Závěr

The USP meloxicam assay and impurity methods were successfully implemented on the Nexera XR system, meeting all suitability requirements. The ACTO module effectively adjusted gradient delays, ensuring reproducible results across Shimadzu HPLC platforms without hardware modification.

Reference

• United States Pharmacopeia 40–NF 35, 2017